Background
==========

Non-alcoholic fatty liver disease (NAFLD) is considered to be the most common cause of chronic liver dysfunction and the most frequent cause of asymptomatic abnormalities, accounting for 26.4% of positive liver enzymes in laboratory investigations \[[@b1-medscimonit-18-12-cr735]\]. It is thought that at present NAFLD affects 9%--30% of people in the developed countries; the prevalence of NAFLD is higher than 30% in the adult U.S. population \[[@b2-medscimonit-18-12-cr735]--[@b6-medscimonit-18-12-cr735]\]. NAFLD has been found to affect 10% of the population under 18 years of age \[[@b7-medscimonit-18-12-cr735]\].

NAFLD represents a very wide clinical spectrum. It includes: simple fatty liver, in which lipids constitute over 5% of the liver weight; and non-alcoholic steatohepatitis (NASH), which may progress to cirrhosis, with all the dire consequences resulting from the compromised activity of hepatocytes and portal hypertension. It is estimated that NASH is present in 3--5% of the population worldwide \[[@b8-medscimonit-18-12-cr735]\]. The presence of advanced fibrosis that accompanies NASH will inevitably lead to the development of cirrhosis and hepatocellular carcinoma \[[@b9-medscimonit-18-12-cr735]--[@b14-medscimonit-18-12-cr735]\]. Thus, identification of patients with advanced fibrosis in the course of NAFLD is essential. To date biopsy has been regarded the "gold standard" for diagnosis and assessment of liver fibrosis \[[@b15-medscimonit-18-12-cr735]\]. However, the method is expensive, invasive, and has certain limitations; therefore biopsy is no longer considered the obligatory and primary screening for diagnosis of NAFLD \[[@b8-medscimonit-18-12-cr735],[@b16-medscimonit-18-12-cr735]--[@b19-medscimonit-18-12-cr735]\].

Introduction of new tests, such as the FibroTest-ActiTest (2001), followed by FibroMax, transient elastography, and other noninvasive fibrosis biomarkers, enabled diagnosticians to change the diagnostic procedures used in patients with NAFLD.

Although the search for other noninvasive markers of liver fibrosis, helpful in identifying patients with advanced fibrosis, has been successful, all the methods have significant limitations. The noninvasive markers of liver fibrosis include: the NAFLD fibrosis score, BARD score, Original European Liver Fibrosis Panel (OELF) score, Enhanced Liver Fibrosis (ELF) score, HAIR score, Palekar's score, BAAT score, Gholam's score, and Nippon score \[[@b20-medscimonit-18-12-cr735]--[@b27-medscimonit-18-12-cr735]\]. They are based on readily available laboratory tests. Some of them are easy to carry out, while others are merely of scientific value.

The aim of this study was to compare the usefulness of the NAFLD fibrosis score and the BARD score in predicting the results of liver fibrosis in Polish patients with NAFLD, from eastern Poland, and to determine the risk factors of advanced fibrosis. The 2 scores have been chosen because they include 7 parameters (more than the other scores mentioned), and thus are likely to be more reliable. Moreover, the scores are inexpensive and widely available.

Material and Methods
====================

The study encompassed 126 patients with NAFLD, including 53 females (42.1%) and 73 males (57.9%). The patients were recruited from the Department of Gastroenterology, Medical University of Lublin. The study population was an ethnically homogenous Caucasian group of patients from eastern Poland. The mean age of patients was 42.7±13.94 years, 41.2±7.6 in females and 43±11.7 years in males. The study was conducted prospectively. Diagnosis of NAFLD was based on an elevated level of ALT and AST, and liver biopsy showing steatosis in at least 5% of hepatocytes, according to the histological criteria for NAFLD by Kleiner et al. \[[@b28-medscimonit-18-12-cr735]\] and Tiniakos \[[@b29-medscimonit-18-12-cr735]\], and alcohol intake lower than 20 g/day in women and 30 g/day in men, obtained during history taking and confirmed by family members.

Other causes of chronic liver diseases (HBV, HCV, autoimmune, primary liver cirrhosis, Wilson disease, hemochromatosis, drug-induced, etc.) were excluded using the specific clinical, biochemical, radiological and histological criteria.

Liver biopsy was evaluated by the same liver pathologist, and fibrosis was scored on a 5-point scale suggested by Kleiner et al. \[[@b28-medscimonit-18-12-cr735]\], in which stage F0 = absence of fibrosis, F1 = perisinusoidal or periportal fibrosis, F2 = perisinusoidal and portal/periportal fibrosis, F3 = bridging fibrosis, and F4 = cirrhosis. Stages F0, F1, F2 were considered as mild/moderate fibrosis and stages F3 and F4 as advanced fibrosis. On the basis of the histology findings, the studied patients were divided into 2 groups: mild/moderate, and advanced fibrosis.

Levels of AST, ALT, serum albumin and platelet count were determined in all patients. The AST/ALT ratio, BMI, BARD score and NAFLD fibrosis score were calculated for each patient. BMI was calculated using the formula: weight (in kilograms)/height (in meters^2^). Obesity was diagnosed when BMI was ≥30 kg/m^2^, and overweight when BMI was ≥25 and \<30 kg/m^2^.

The NAFLD fibrosis score formula was = −1.675 + 0.037 -- age (years) + 0.094 -- BMI (kg/m^2^) + 1.13 × IFG/diabetes (yes = 1, no = 0) + 0.99 × AST/ALT ratio -- 0.013 × platelet count (×10^9^/l) -- 0.66 × albumin (g/dl). Diabetes mellitus was diagnosed when fasting glucose was ≥126 mg/dl or the patient was treated with anti-diabetic drugs, or had IFG -- when the fasting glucose level ranged between 100 and 125 mg/dL. In each patient with diabetes mellitus or IFG, the level of glycosylated hemoglobin (HbA1C) was determined. According to Angulo et al, a score lower than --1.455 (low cutoff) excludes advanced fibrosis, whereas a score higher than 0.676 (high cutoff) predicts advanced fibrosis. Scores between these values are defined as indeterminate \[[@b21-medscimonit-18-12-cr735]\].

The BARD score was composed of 3 variables: AST/ALT ratio ≥0.8--2 points; a BMI ≥28 -- 1 point; and the presence of diabetes -- 1 point. The possible score ranges from 0 to 4 points. According to the results of Harrison et al., BARD scores equaling 0 or 1 are of high (96%) negative predictive value (NPV) for advanced fibrosis \[[@b20-medscimonit-18-12-cr735]\]. Variables necessary for the assessment of scores (age, BMI) and laboratory analysis (fasting plasma glucose, AST, ALT, platelet count, and serum albumin) were determined the day before the liver biopsy. The results of NAFLD fibrosis score and BARD score were compared with the liver biopsy findings.

The study was approved by the Local Ethics Committee and all the subjects gave written informed consent for examinations.

Statistical analysis
--------------------

Quantitative variables are presented as a mean and standard deviation (SD). Quantitative variables were compared between the groups using Student's t-test, and qualitative variables using the chi-square test. Statistical significance was assumed at p\<0.05. Adjusted odds ratios (OR), 95% confidence intervals (95% CI), negative and positive predictive values, and AUROC (area under receiver operator characteristic) curve for BARD and NAFLD scores were calculated. All calculations were carried out using MedCal software version 12.0.

Results
=======

Clinical, biochemical and histological data of the examined patients are illustrated in [Table 1](#t1-medscimonit-18-12-cr735){ref-type="table"}. The histological findings revealed that 27 out of 126 patients were affected with advanced fibrosis (F=3, F=4), whereas 99 had mild/moderate fibrosis (F=0, F=1, F=2). In our study, liver biopsy demonstrated the presence of cirrhosis in 3 patients (F4=3). Comparison of the selected biochemical and clinical features between the studied groups of patients with advanced and mild/moderate fibrosis showed statistically significant differences in the following parameters: age, BMI (obesity and overweight), the presence of IFG or diabetes mellitus, AST activity, AST/ALT ratio, and platelet count ([Table 2](#t2-medscimonit-18-12-cr735){ref-type="table"}). Diabetes mellitus was diagnosed in 29 patients, and IFG in none. The mean level of HbA1C in this group of patients was 6.93±0.94%.

Advanced fibrosis was statistically significantly more common in the older patients, with BMI usually \>30 kg/m^2^ and high AST/ALT ratio. In this group of patients, diabetes mellitus was 6 times more frequent in comparison with the patients with mild/moderate fibrosis. Age ≥50 years, obesity (BMI ≥30 kg/m^2^), AST/ALT ratio ≥0.8, diabetes mellitus, and platelet count ≤200 (×10^3^/L) were the statistically significant risk factors for advanced liver fibrosis ([Table 3](#t3-medscimonit-18-12-cr735){ref-type="table"}).

The BARD scores demonstrated 35 patients with high scores -- ≥2 points (2 points -- 18 patients, 3 points -- 13 patients, 4 points -- 4 patients), and 91 patients with low scores -- 0 points -- 52 patients, 1 point -- 39 patients). Liver biopsy helped to diagnose advanced fibrosis in 24 patients (F3=21, F4=3) out of 35 whose BARD scores were 2 points or higher. Analysis of BARD scores 0 or 1 revealed advanced fibrosis (F3) in 3 patients; in the remaining 88 patients only mild/moderate fibrosis was diagnosed (F0--30 patients, F1--40 patients and F2--18 patients). Analysis of the NAFLD fibrosis score revealed 34 patients with scores higher than 0.676, 53 patients lower than −1.455, and 39 patients with indeterminate scores (30.9%). In the group of patients with high NAFLD fibrosis score (over 0.676), 24 had advanced fibrosis (F3=21, F4=3), and another 10 patients had mild/moderate fibrosis (2 patients-F0, 5 patients −F1 and 3 patients-F2). In the group of patients with low scores (lower than −1.455) 1 patient had advanced fibrosis demonstrated by liver biopsy. The accuracy of BARD and NAFLD fibrosis scores is presented in [Table 4](#t4-medscimonit-18-12-cr735){ref-type="table"}.

Discussion
==========

Assessment of advanced fibrosis in the course of NAFLD is of vital practical and prognostic significance; therefore, identification of these patients is of utmost importance. To avoid liver biopsy, a highly invasive procedure, new simple and noninvasive diagnostic methods to diagnose advanced liver fibrosis are being searched for (30). Among the tests that could be useful, the NAFLD fibrosis score and the BARD score give promising results.

Harrison et al. \[[@b20-medscimonit-18-12-cr735]\] found high values of NPV (96%) in patients with low BARD scores, which enabled identification of patients without advanced fibrosis. According to Angulo et al \[[@b21-medscimonit-18-12-cr735]\], NPV and PPV for the NAFLD fibrosis score were high -- NPV ≥87% and PPV -- ≥78%, respectively. Some results were still indeterminate (NAFLD fibrosis scores between −1.455 and 0.676); thus, these patients require liver biopsy to assess liver fibrosis severity.

Our studies have shown that both the BARD and NAFLD fibrosis scores have relatively high sensitivity and specificity. Moreover, both of them showed very high values of NPV (ie, 96.70% and 98.11%, respectively) and were very similar to the results reported by McPherson's et al. \[[@b31-medscimonit-18-12-cr735]\], Raszeja-Wyszomirska et al. \[[@b32-medscimonit-18-12-cr735]\], and a Chinese study \[[@b33-medscimonit-18-12-cr735]\]. Compared to our findings, NPV found in Argentinian patients was lower -- 81.3% for both BARD and NAFLD fibrosis scores \[[@b34-medscimonit-18-12-cr735]\]. Moreover, PPV was lower than NPV, comparable to other study results -- 68.57% for the BARD score and 70.59% for the NAFLD score. Our findings identified 30.9% of patients whose results were indeterminate. The percentage of such patients was similar to the results of other studies \[[@b33-medscimonit-18-12-cr735],[@b34-medscimonit-18-12-cr735]\].

According to Wong et al. \[[@b33-medscimonit-18-12-cr735]\], implementation of the NAFLD fibrosis score to the Chinese population should help avoid liver biopsy in 79% of patients. The researchers emphasize the role this parameter plays in primary health care, since it provides certain data necessary for identification of those patients with NAFLD who require livery biopsy for diagnosis of advanced fibrosis and assessment of its severity \[[@b1-medscimonit-18-12-cr735]\].

Otherwise, McPherson et al. \[[@b31-medscimonit-18-12-cr735]\] believe that the FIB-4 test has the best diagnostic value, although only slightly better than that of the BARD and NAFLD fibrosis scores (age × AST \[IU/l\]/platelet count \[×10^9^/litre\] × radical ALT \[IU/l\]). In the FIB-4 test, the AUROC curve is 0.86, while in the BARD and NAFLD fibrosis scores were 0.77 and 0.81, respectively. According to the authors, FIB-4 tests can rule out advanced liver fibrosis beyond any doubt; thus liver biopsy is avoidable in 62% of patients, as compared to 52% based on the NAFLD fibrosis score (69.1% in our study) and only 38% based on the BARD score. Moreover, Shah et al. \[[@b35-medscimonit-18-12-cr735]\] also found the FIB-4 index superior to 7 other non-invasive markers of fibrosis in NAFLD \[[@b32-medscimonit-18-12-cr735]\]. In their study, the AUROC curve for the BARD and the NAFLD fibrosis scores, and the FIB-4 index, were 0.700, 0.768 and 0.802, respectively. Importantly, our results showed that the AUROC curve for the BARD and NAFLD fibrosis scores was much higher compared to the 2 other studies. The AUROC curve for both scores was as high as for the FIB-4 in the study by McPherson et al. \[[@b31-medscimonit-18-12-cr735]\] and much higher than that reported by Shah et al. \[[@b35-medscimonit-18-12-cr735]\].

Another useful technique for assessment of advanced liver fibrosis is ultrasound-based transient elastography (Fibroscan), which shows a significant correlation between liver stiffness measurements and fibrosis staging confirmed by liver biopsy in NAFLD patients \[[@b36-medscimonit-18-12-cr735]\]. It is a non-invasive procedure, but has some significant limitations in obese patients \[[@b37-medscimonit-18-12-cr735]\]. The failure rate is 2--10% of patients with BMI ≥30 kg/m^2^. The currently available procedure is designed only for patients with standard morphology. A newly developed XL probe provides higher accuracy of advanced fibrosis evaluation in patients with increased BMI and shows promising results, yet has not been widely used. In the near future it is likely to become the gold standard for diagnosis of advanced fibrosis, and can eliminate the need for liver biopsy and the other non-invasive markers.

The literature contains only a few reports concerning the risk factors of advanced fibrosis. According to our findings, age ≥50 years, obesity (BMI ≥30 kg/m^2^), diabetes mellitus, and the platelet count ≤200 (×10^9^/L) favored the development of advanced fibrosis. The AST/ALT ratio ≥0.8 was a particularly important factor -- OR for it was 20. Likewise, Ong et al. \[[@b38-medscimonit-18-12-cr735]\] demonstrated that obesity, as a component of metabolic syndrome, was independently associated with advanced fibrosis. There are reports, however, that found no relationship between BMI, diabetes mellitus, and aced fibrosis \[[@b32-medscimonit-18-12-cr735],[@b38-medscimonit-18-12-cr735]\]. In one of them the differences can be related to the fact that BMI ≥28 kg/m^2^ was considered a risk factor of advanced fibrosis, and not BMI ≥30 kg/m^2^ as in our study \[[@b32-medscimonit-18-12-cr735]\]. We found that only obesity and not overweight was associated with advanced liver fibrosis. In the other study statistical significance was not demonstrated due to the small number of patients \[[@b39-medscimonit-18-12-cr735]\].

Conclusions
===========

Our study results reveal that BARD and NAFLD fibrosis scores have high NPV values, are capable of excluding advanced liver fibrosis and markedly reducing the incidence of liver biopsies in patients with NAFLD. This invasive procedure is required only in a certain group of patients. Obesity, diabetes mellitus, more advanced age, platelet count ≤200×10^9^/L, and AST/ALT ratio = 0.8 or higher are considered the risk factors of advanced fibrosis in patients with NAFLD.

**Source of support:** Departmental sources

###### 

Clinical, biochemical and histological data of examined patients.

  Parameter                         Mean ±SD
  --------------------------------- ---------------
  Age (years)                       42.7±13.94
  Gender: female/male (n)           53/73
  ALT (U/L)                         97.51±61.96
  AST (U/L)                         68.29±51.57
  AST/ALT ratio                     0.72±0.38
  Albumin (g/dL)                    4.3±0.47
  Platelets (x 10^9^/L)             276.94±80.03
  BMI (kg/m^2^)                     28.51±2.67
  Obesity (n/%) (BMI ≥30 kg/m^2^)   24/19.05
  Overweight (n/%)                  
  (BMI ≥25 and \<30 kg/m^2)^        81/64.29
  Diabetes mellitus (n/%)           29/23.02
  Fibrosis F0/F1/F2/F3/F4 (n)       33/45/21/24/3

n -- number of cases; ALT -- alanine aminotransferase; AST -- aspartate aminotransferase; BMI -- body mass index.

###### 

Comparison of selected clinical and biochemical parameters between patients with mild/moderate and advanced fibrosis.

  Parameter                                                                           Mild/moderate fibrosis F0--F2 (n=99)   Advanced fibrosis F3--F4 (n=27)   P value
  ----------------------------------------------------------------------------------- -------------------------------------- --------------------------------- ----------
  Age (years)[\*](#tfn2-medscimonit-18-12-cr735){ref-type="table-fn"}                 43.01±13.43                            50.89±11.37                       0.00618
  Gender: female/male (%)                                                             40.4/59.6                              44.4/55.6                         0.5666
  BMI (kg/m^2^)[\*](#tfn2-medscimonit-18-12-cr735){ref-type="table-fn"}               27.85±2.51                             32.6±3.36                         0.00087
  Obesity (%/n) (BMI ≥30 kg/m^2^)                                                     11.1/11                                48.15/13                          0.0110
  Overweight (%/n) (BMI ≥25 and \<30kg/m^2)^                                          81.81/70                               44.44/12                          0.0013
  Diabetes mellitus (%/n)                                                             11.1/11                                66.6/18                           0.0067
  ALT (U/L)[\*](#tfn2-medscimonit-18-12-cr735){ref-type="table-fn"}                   94.81±60.38                            104.81±67.71                      0.45904
  AST (U/L)[\*](#tfn2-medscimonit-18-12-cr735){ref-type="table-fn"}                   59.41±45.95                            94.41±54.16                       0.00099
  AST/ALT ratio[\*](#tfn2-medscimonit-18-12-cr735){ref-type="table-fn"}               0.66±0.29                              1.08±0.46                         0.000041
  Albumin (g/dL)[\*](#tfn2-medscimonit-18-12-cr735){ref-type="table-fn"}              4.34±0.48                              4.22±0.42                         0.2537
  Platelet count (×10^9^/L)[\*](#tfn2-medscimonit-18-12-cr735){ref-type="table-fn"}   292.51±79.73                           219.44±69.32                      0.00003

Mean ± standard deviation;

ALT -- alanine aminotransferase; AST -- aspartate aminotransferase; BMI -- body mass index; n -- number of cases.

###### 

Assessment of risk factors for advanced fibrosis.

  Parameter                              Mild/moderate fibrosis F0--F2 (n=99)   Advanced fibrosis F3--F4 (n=27)   P value   OR      95% Cl
  -------------------------------------- -------------------------------------- --------------------------------- --------- ------- -------------
  Age ≥ 50 (years) (n/%)                 33/33.33%                              18/66.66%                         0.0018    4.0     1.50--10.08
  Female (n/%)                           40/40.4%                               12/44.4%                          0.7054    1.18    0.80--1.75
  Male (n/%)                             59/59.6%                               16/55.6%                          0.9748    0.99    0.67--1.47
  BMI ≥25 kg/m^2^ (n/%)                  81/81.82%                              25/92.59%                         0.1745    2.78    0.86--8.90
  BMI ≥30 kg/m^2^ (n/%)                  11/11.11%                              13/48.15%                         0.0000    7.43    4.12--13.37
  AST/ALT ratio ≥0.8                     9/9.09%                                18/66.66%                         0.0000    20.00   11.1--36.0
  Diabetes mellitus (n/%)                11/11.1%                               18/66.6%                          0.0000    16.00   8.88--28.8
  Platelet count ≤200 (×10^9^/L) (n/%)   9/9.09%                                11/40.74%                         0.0001    6.88    3.82--12.38

n -- number of cases; BMI -- body mass index.

###### 

Accuracy of BARD and NAFLD fibrosis scores for predicting advanced fibrosis.

  ---------------------------------------------------------
  Parameter     BARD score           NAFLD fibrosis score
  ------------- -------------------- ----------------------
  Sensitivity   88.89%               96.00%

  Specificity   88.89%               83.87%

  PPV           68.57%               70.59%

  NPV           96.70%               98.11%

  AUROC curve   0.865 (p\<0.0001)\   0.919 (p\<0.0001)\
                OR=9.479\            OR=17.81\
                95%CI=0.793--0.920   95%CI=0.841--0.967
  ---------------------------------------------------------

PPV -- positive predictive value; NPV -- negative predictive value; AUROC curve -- area under receiver operator characteristic curve.
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